{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:11:37Z","timestamp":1789071097376,"version":"build-2803163510"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10378-3","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:41:42Z","timestamp":1789026102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8693-9291","authenticated-orcid":false,"given":"Quan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0030","authenticated-orcid":false,"given":"Jiancheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"22","key":"10378_CR1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile, J. F., et al. (2016). Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 127(22), 2672\u20132681.","journal-title":"Blood"},{"key":"10378_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100454","volume":"36","author":"X Hu","year":"2022","unstructured":"Hu, X., et al. (2022). Langerhans cell histiocytosis: A population-based study of anatomical distribution and treatment patterns. Journal of Bone Oncology, 36, Article 100454.","journal-title":"Journal of Bone Oncology"},{"issue":"5","key":"10378_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/bjh.18459","volume":"199","author":"H Liu","year":"2022","unstructured":"Liu, H., et al. (2022). Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013\u20132019. British Journal of Haematology, 199(5), 728\u2013738.","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10378_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/adc.2008.144527","volume":"94","author":"JA Salotti","year":"2009","unstructured":"Salotti, J. A., et al. (2009). Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Archives of Disease in Childhood, 94(5), 376\u201380.","journal-title":"Archives of Disease in Childhood"},{"issue":"1","key":"10378_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/pbc.21504","volume":"51","author":"H Stalemark","year":"2008","unstructured":"Stalemark, H., et al. (2008). Incidence of Langerhans cell histiocytosis in children: A population-based study. Pediatric Blood & Cancer, 51(1), 76\u201381.","journal-title":"Pediatric Blood & Cancer"},{"issue":"5","key":"10378_CR6","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","volume":"111","author":"H Gadner","year":"2008","unstructured":"Gadner, H., et al. (2008). Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood, 111(5), 2556\u20132562.","journal-title":"Blood"},{"issue":"12","key":"10378_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/onco.13541","volume":"25","author":"AZ Hazim","year":"2020","unstructured":"Hazim, A. Z., et al. (2020). Efficacy of BRAF-inhibitor therapy in BRAF(V600E) -mutated adult Langerhans cell histiocytosis. The Oncologist, 25(12), 1001\u20131004.","journal-title":"The Oncologist"},{"issue":"4","key":"10378_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3324\/haematol.2023.283295","volume":"109","author":"E Cournoyer","year":"2024","unstructured":"Cournoyer, E., et al. (2024). Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Haematologica, 109(4), 1137\u20131148.","journal-title":"Haematologica"},{"key":"10378_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275085","volume":"14","author":"T Sconocchia","year":"2023","unstructured":"Sconocchia, T., et al. (2023). Langerhans cell histiocytosis: Current advances in molecular pathogenesis. Frontiers in Immunology, 14, Article 1275085.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10378_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4143\/crt.2024.782","volume":"57","author":"KN Koh","year":"2025","unstructured":"Koh, K. N., et al. (2025). Unraveling the genetic landscape of Langerhans cell histiocytosis in Korean patients: Comprehensive insights from mutational profiles and clinical correlations. Cancer Research and Treatment, 57(3), 873\u2013882.","journal-title":"Cancer Research and Treatment"},{"issue":"6892","key":"10378_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949\u2013954.","journal-title":"Nature"},{"issue":"6","key":"10378_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/gcc.22247","volume":"54","author":"DS Nelson","year":"2015","unstructured":"Nelson, D. S., et al. (2015). MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes, Chromosomes & Cancer, 54(6), 361\u2013368.","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"11","key":"10378_CR13","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1055-9965.EPI-06-0359","volume":"15","author":"J Vandrovcova","year":"2006","unstructured":"Vandrovcova, J., et al. (2006). Somatic BRAF-V600E mutations in familial colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention, 15(11), 2270\u20132273.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"1","key":"10378_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si, L., et al. (2012). Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. European Journal of Cancer, 48(1), 94\u2013100.","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10378_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000490699","volume":"7","author":"L Damiani","year":"2018","unstructured":"Damiani, L., et al. (2018). Evaluation of the role of BRAFV600E somatic mutation on papillary thyroid cancer disease persistence: A prospective study. European Thyroid Journal, 7(5), 251\u2013257.","journal-title":"European Thyroid Journal"},{"issue":"3","key":"10378_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ccr.2014.07.007","volume":"26","author":"JR Haling","year":"2014","unstructured":"Haling, J. R., et al. (2014). Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell, 26(3), 402\u2013413.","journal-title":"Cancer Cell"},{"issue":"3","key":"10378_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","volume":"10","author":"ER Cantwell-Dorris","year":"2011","unstructured":"Cantwell-Dorris, E. R., O\u2019Leary, J. J., & Sheils, O. M. (2011). BRAFV600E: Implications for carcinogenesis and molecular therapy. Molecular Cancer Therapeutics, 10(3), 385\u201394.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10378_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010198","author":"U Degirmenci","year":"2020","unstructured":"Degirmenci, U., Wang, M., & Hu, J. (2020). Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy. Cells. https:\/\/doi.org\/10.3390\/cells9010198","journal-title":"Cells"},{"issue":"43","key":"10378_CR19","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1038\/s41388-018-0365-2","volume":"37","author":"J Yuan","year":"2018","unstructured":"Yuan, J., et al. (2018). The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants. Oncogene, 37(43), 5719\u20135734.","journal-title":"Oncogene"},{"issue":"10","key":"10378_CR20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown, N. A., et al. (2014). High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood, 124(10), 1655\u20131658.","journal-title":"Blood"},{"issue":"1","key":"10378_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41467-022-28084-3","volume":"13","author":"JA Martinez Fiesco","year":"2022","unstructured":"Martinez Fiesco, J. A., et al. (2022). Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nature Communications, 13(1), 486.","journal-title":"Nature Communications"},{"key":"10378_CR22","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.95334.4","author":"J Clayton","year":"2025","unstructured":"Clayton, J., et al. (2025). Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors. eLife. https:\/\/doi.org\/10.7554\/eLife.95334.4","journal-title":"eLife"},{"key":"10378_CR23","doi-asserted-by":"publisher","unstructured":"Varga, A., et al. (2017). RAF1\/BRAF dimerization integrates the signal from RAS to ERK and ROKalpha. Science Signal, 10(469):eaai8482. https:\/\/doi.org\/10.1126\/scisignal.aai8482","DOI":"10.1126\/scisignal.aai8482"},{"issue":"6","key":"10378_CR24","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1128\/MCB.26.6.2262-2272.2006","volume":"26","author":"LK Rushworth","year":"2006","unstructured":"Rushworth, L. K., et al. (2006). Regulation and role of Raf-1\/B-Raf heterodimerization. Molecular and Cellular Biology, 26(6), 2262\u201372.","journal-title":"Molecular and Cellular Biology"},{"key":"10378_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aar6795","author":"J Yuan","year":"2018","unstructured":"Yuan, J., et al. (2018). Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis. Science Signaling. https:\/\/doi.org\/10.1126\/scisignal.aar6795","journal-title":"Science Signaling"},{"issue":"1","key":"10378_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1084\/jem.20161881","volume":"215","author":"B Hogstad","year":"2018","unstructured":"Hogstad, B., et al. (2018). RAF\/MEK\/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Journal of Experimental Medicine, 215(1), 319\u2013336.","journal-title":"Journal of Experimental Medicine"},{"issue":"2","key":"10378_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1634\/theoncologist.2013-0341","volume":"19","author":"FM Rizzo","year":"2014","unstructured":"Rizzo, F. M., et al. (2014). New insights into the molecular pathogenesis of Langerhans cell histiocytosis. The Oncologist, 19(2), 151\u2013163.","journal-title":"The Oncologist"},{"issue":"8","key":"10378_CR28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1182\/blood.2024026066","volume":"145","author":"G Abagnale","year":"2025","unstructured":"Abagnale, G., et al. (2025). BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses. Blood, 145(8), 850\u2013865.","journal-title":"Blood"},{"issue":"4","key":"10378_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres, M. L., et al. (2014). BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine, 211(4), 669\u2013683.","journal-title":"Journal of Experimental Medicine"},{"issue":"2","key":"10378_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood.2024026671","volume":"146","author":"H Lin","year":"2025","unstructured":"Lin, H., et al. (2025). BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood, 146(2), 206\u2013218.","journal-title":"Blood"},{"issue":"2","key":"10378_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood-2016-12-757823","volume":"130","author":"P Milne","year":"2017","unstructured":"Milne, P., et al. (2017). Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood, 130(2), 167\u2013175.","journal-title":"Blood"},{"issue":"11","key":"10378_CR32","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/s41375-023-02019-3","volume":"37","author":"T Sconocchia","year":"2023","unstructured":"Sconocchia, T., et al. (2023). BRAF(V600E) promotes DC3\/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis. Leukemia, 37(11), 2292\u20132296.","journal-title":"Leukemia"},{"issue":"9","key":"10378_CR33","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","volume":"121","author":"J Haroche","year":"2013","unstructured":"Haroche, J., et al. (2013). Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 121(9), 1495\u20131500.","journal-title":"Blood"},{"issue":"31","key":"10378_CR34","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1200\/JCO.19.00456","volume":"37","author":"J Donadieu","year":"2019","unstructured":"Donadieu, J., et al. (2019). Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: An international observational study. Journal of Clinical Oncology, 37(31), 2857\u20132865.","journal-title":"Journal of Clinical Oncology"},{"issue":"7749","key":"10378_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","volume":"567","author":"EL Diamond","year":"2019","unstructured":"Diamond, E. L., et al. (2019). Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 567(7749), 521\u2013524.","journal-title":"Nature"},{"issue":"6","key":"10378_CR36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12185-021-03205-8","volume":"114","author":"D Evseev","year":"2021","unstructured":"Evseev, D., et al. (2021). Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. International Journal of Hematology, 114(6), 725\u2013734.","journal-title":"International Journal of Hematology"},{"issue":"1","key":"10378_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4143\/crt.2020.769","volume":"53","author":"Y Yang","year":"2021","unstructured":"Yang, Y., et al. (2021). Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAFV600E-mutated Langerhans cell histiocytosis. Cancer Research and Treatment, 53(1), 261\u2013269.","journal-title":"Cancer Research and Treatment"},{"issue":"15","key":"10378_CR38","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","volume":"7","author":"JA Whitlock","year":"2023","unstructured":"Whitlock, J. A., et al. (2023). Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Blood Advances, 7(15), 3806\u20133815.","journal-title":"Blood Advances"},{"issue":"3","key":"10378_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/pde.15512","volume":"41","author":"G Benjelloun","year":"2024","unstructured":"Benjelloun, G., et al. (2024). Treatment of congenital Langerhans cell histiocytosis with cobimetinib. Pediatric Dermatology, 41(3), 515\u2013517.","journal-title":"Pediatric Dermatology"},{"issue":"142","key":"10378_CR40","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1182\/blood-2023-184911","volume":"142","author":"G Goyal","year":"2023","unstructured":"Goyal, G., et al. (2023). Outcomes with MEK inhibitor therapy among adults with Langerhans cell histiocytosis (LCH): A multi-institutional study from the Adult LCH Working Group for the Histiocyte Society. Blood, 142(142), 4559.","journal-title":"Blood"},{"issue":"8526","key":"10378_CR41","first-page":"208","volume":"1","author":"Histiocytosis syndromes in children","year":"1987","unstructured":"Histiocytosis syndromes in children. (1987). Writing Group of the Histiocyte Society. Lancet, 1(8526), 208\u2013209.","journal-title":"Lancet"},{"issue":"7","key":"10378_CR42","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","volume":"124","author":"B Hervier","year":"2014","unstructured":"Hervier, B., et al. (2014). Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood, 124(7), 1119\u20131126.","journal-title":"Blood"},{"issue":"2","key":"10378_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt, R., et al. (2013). Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatric Blood & Cancer, 60(2), 175\u2013184.","journal-title":"Pediatric Blood & Cancer"},{"key":"10378_CR44","doi-asserted-by":"publisher","first-page":"1452003","DOI":"10.3389\/fmed.2024.1452003","volume":"11","author":"Y Lu","year":"2024","unstructured":"Lu, Y., et al. (2024). Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: A single-center retrospective study. Front Med (Lausanne), 11, 1452003.","journal-title":"Front Med (Lausanne)"},{"issue":"25","key":"10378_CR45","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","volume":"34","author":"S Heritier","year":"2016","unstructured":"Heritier, S., et al. (2016). BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. Journal of Clinical Oncology, 34(25), 3023\u20133030.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10378_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4132\/jptm.2020.11.30","volume":"55","author":"TDA Phan","year":"2021","unstructured":"Phan, T. D. A., et al. (2021). A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children. J Pathol Transl Med, 55(2), 112\u2013117.","journal-title":"J Pathol Transl Med"},{"issue":"7","key":"10378_CR47","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00277-019-03678-y","volume":"98","author":"D Nann","year":"2019","unstructured":"Nann, D., et al. (2019). Pediatric Langerhans cell histiocytosis: The impact of mutational profile on clinical progression and late sequelae. Annals of Hematology, 98(7), 1617\u20131626.","journal-title":"Annals of Hematology"},{"issue":"18","key":"10378_CR48","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood.2023021212","volume":"142","author":"AA Acosta-Medina","year":"2023","unstructured":"Acosta-Medina, A. A., et al. (2023). BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. Blood, 142(18), 1570\u20131575.","journal-title":"Blood"},{"issue":"11","key":"10378_CR49","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very, G., et al. (2010). Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood, 116(11), 1919\u20131923.","journal-title":"Blood"},{"issue":"1","key":"10378_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-017-0690-z","volume":"16","author":"S Heritier","year":"2017","unstructured":"Heritier, S., et al. (2017). New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer, 16(1), 115.","journal-title":"Molecular Cancer"},{"issue":"4","key":"10378_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033891","volume":"7","author":"T Satoh","year":"2012","unstructured":"Satoh, T., et al. (2012). B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE, 7(4), Article e33891.","journal-title":"PLoS ONE"},{"issue":"3","key":"10378_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89473","volume":"2","author":"LH Lee","year":"2017","unstructured":"Lee, L. H., et al. (2017). Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight, 2(3), Article e89473.","journal-title":"JCI Insight"},{"key":"10378_CR53","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01190-2019","author":"F Jouenne","year":"2020","unstructured":"Jouenne, F., et al. (2020). Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. European Respiratory Journal. https:\/\/doi.org\/10.1183\/13993003.01190-2019","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10378_CR54","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2340\/00015555-2674","volume":"97","author":"E Crickx","year":"2017","unstructured":"Crickx, E., et al. (2017). Clinical spectrum, quality of life, BRAF mutation status and treatment of skin involvement in adult Langerhans cell histiocytosis. Acta Dermato-Venereologica, 97(7), 838\u2013842.","journal-title":"Acta Dermato-Venereologica"},{"issue":"12","key":"10378_CR55","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","volume":"25","author":"BH Durham","year":"2019","unstructured":"Durham, B. H., et al. (2019). Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 25(12), 1839\u20131842.","journal-title":"Nature Medicine"},{"issue":"24","key":"10378_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70532","volume":"13","author":"X Tang","year":"2024","unstructured":"Tang, X., et al. (2024). Beyond BRAF(V600E): Investigating the clinical and genetic spectrum of Langerhans cell histiocytosis in children. Cancer Medicine, 13(24), Article e70532.","journal-title":"Cancer Medicine"},{"issue":"1","key":"10378_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1535370220959657","volume":"246","author":"J Owsley","year":"2021","unstructured":"Owsley, J., et al. (2021). Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Experimental Biology and Medicine (Maywood, N.J.), 246(1), 31\u201339.","journal-title":"Experimental Biology and Medicine (Maywood, N.J.)"},{"issue":"21","key":"10378_CR58","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood-2016-08-733790","volume":"128","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty, R., et al. (2016). Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood, 128(21), 2533\u20132537.","journal-title":"Blood"},{"issue":"6","key":"10378_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-022-00693-7","volume":"12","author":"S Zanwar","year":"2022","unstructured":"Zanwar, S., et al. (2022). Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer Journal, 12(6), 97.","journal-title":"Blood Cancer Journal"},{"key":"10378_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26699","author":"S Zarnegar","year":"2018","unstructured":"Zarnegar, S., et al. (2018). Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric Blood & Cancer. https:\/\/doi.org\/10.1002\/pbc.26699","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10378_CR61","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5858\/arpa.2023-0236-OA","volume":"149","author":"CJ Wang","year":"2025","unstructured":"Wang, C. J., et al. (2025). Genetic landscape and its prognostic impact in children with Langerhans cell histiocytosis. Archives of Pathology & Laboratory Medicine, 149(2), 175\u2013190.","journal-title":"Archives of Pathology & Laboratory Medicine"},{"issue":"3","key":"10378_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70067","volume":"6","author":"M Lang","year":"2025","unstructured":"Lang, M., Chang, L., & Cao, X. X. (2025). Langerhans cell histiocytosis with MAP2K1(E102_I103del) mutation successfully treated with trametinib. EJHaem, 6(3), Article e70067.","journal-title":"EJHaem"},{"issue":"9","key":"10378_CR63","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00432-021-03810-4","volume":"148","author":"Y Yang","year":"2022","unstructured":"Yang, Y., et al. (2022). Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children. Journal of Cancer Research and Clinical Oncology, 148(9), 2517\u20132527.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"5","key":"10378_CR64","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2159-8290.CD-17-1452","volume":"8","author":"Y Gao","year":"2018","unstructured":"Gao, Y., et al. (2018). Allele-specific mechanisms of activation of MEK1 mutants determine their properties. Cancer Discovery, 8(5), 648\u2013661.","journal-title":"Cancer Discovery"},{"issue":"14","key":"10378_CR65","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","volume":"31","author":"K Trunzer","year":"2013","unstructured":"Trunzer, K., et al. (2013). Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology, 31(14), 1767\u20131774.","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10378_CR66","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle, N., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology, 29(22), 3085\u20133096.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10378_CR67","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1038\/s41467-022-31690-w","volume":"13","author":"Y Kubota","year":"2022","unstructured":"Kubota, Y., et al. (2022). Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer. Nature Communications, 13(1), 4063.","journal-title":"Nature Communications"},{"issue":"1","key":"10378_CR68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ccell.2025.09.014","volume":"44","author":"EL Diamond","year":"2026","unstructured":"Diamond, E. L., et al. (2026). RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. Cancer Cell, 44(1), 203-220 e8.","journal-title":"Cancer Cell"},{"issue":"2","key":"10378_CR69","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-021-01439-3","volume":"36","author":"J Chen","year":"2022","unstructured":"Chen, J., et al. (2022). Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis. Leukemia, 36(2), 573\u2013576.","journal-title":"Leukemia"},{"issue":"19","key":"10378_CR70","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty, R., et al. (2014). Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood, 124(19), 3007\u20133015.","journal-title":"Blood"},{"issue":"4","key":"10378_CR71","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/MOH.0000000000000256","volume":"23","author":"BH Durham","year":"2016","unstructured":"Durham, B. H., Diamond, E. L., & Abdel-Wahab, O. (2016). Histiocytic neoplasms in the era of personalized genomic medicine. Current Opinion in Hematology, 23(4), 416\u201325.","journal-title":"Current Opinion in Hematology"},{"issue":"4","key":"10378_CR72","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/15321819.2020.1870132","volume":"42","author":"S Ben Rejeb","year":"2021","unstructured":"Ben Rejeb, S., et al. (2021). Cyclin D1: Potential utility as marker for Langerhans cell histiocytosis. Journal of Immunoassay and Immunochemistry, 42(4), 370\u2013379.","journal-title":"Journal of Immunoassay and Immunochemistry"},{"issue":"2","key":"10378_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1385\/IR:28:2:93","volume":"28","author":"J Valladeau","year":"2003","unstructured":"Valladeau, J., Dezutter-Dambuyant, C., & Saeland, S. (2003). Langerin\/CD207 sheds light on formation of birbeck granules and their possible function in Langerhans cells. Immunology Research, 28(2), 93\u2013107.","journal-title":"Immunology Research"},{"issue":"11","key":"10378_CR74","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.it.2017.06.008","volume":"38","author":"T Doebel","year":"2017","unstructured":"Doebel, T., Voisin, B., & Nagao, K. (2017). Langerhans cells - The macrophage in dendritic cell clothing. Trends in Immunology, 38(11), 817\u2013828.","journal-title":"Trends in Immunology"},{"key":"10378_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00423","volume":"5","author":"I De Kleer","year":"2014","unstructured":"De Kleer, I., et al. (2014). Ontogeny of myeloid cells. Frontiers in Immunology, 5, Article 423.","journal-title":"Frontiers in Immunology"},{"issue":"17","key":"10378_CR76","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood-2017-05-782730","volume":"130","author":"EA Carrera Silva","year":"2017","unstructured":"Carrera Silva, E. A., et al. (2017). CD207(+)CD1a(+) cells circulate in pediatric patients with active Langerhans cell histiocytosis. Blood, 130(17), 1898\u20131902.","journal-title":"Blood"},{"issue":"10","key":"10378_CR77","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/2159-8290.CD-19-0138","volume":"9","author":"F Halbritter","year":"2019","unstructured":"Halbritter, F., et al. (2019). Epigenomics and single-cell sequencing define a developmental hierarchy in Langerhans cell histiocytosis. Cancer Discovery, 9(10), 1406\u20131421.","journal-title":"Cancer Discovery"},{"issue":"1","key":"10378_CR78","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.0105-2896.2009.00883.x","volume":"234","author":"RM Egeler","year":"2010","unstructured":"Egeler, R. M., et al. (2010). Langerhans cell histiocytosis: Fascinating dynamics of the dendritic cell-macrophage lineage. Immunological Reviews, 234(1), 213\u2013232.","journal-title":"Immunological Reviews"},{"issue":"8","key":"10378_CR79","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.4049\/jimmunol.0902336","volume":"184","author":"CE Allen","year":"2010","unstructured":"Allen, C. E., et al. (2010). Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. Journal of Immunology, 184(8), 4557\u20134567.","journal-title":"Journal of Immunology"},{"issue":"5","key":"10378_CR80","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/intimm\/14.5.433","volume":"14","author":"K Takahara","year":"2002","unstructured":"Takahara, K., et al. (2002). Identification and expression of mouse Langerin (CD207) in dendritic cells. International Immunology, 14(5), 433\u2013444.","journal-title":"International Immunology"},{"issue":"1","key":"10378_CR81","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/bloodadvances.2019000488","volume":"4","author":"KPH Lim","year":"2020","unstructured":"Lim, K. P. H., et al. (2020). Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Advances, 4(1), 87\u201399.","journal-title":"Blood Advances"},{"issue":"2","key":"10378_CR82","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.immuni.2020.06.002","volume":"53","author":"P Bourdely","year":"2020","unstructured":"Bourdely, P., et al. (2020). Transcriptional and functional analysis of CD1c(+) human dendritic cells identifies a CD163(+) subset priming CD8(+)CD103(+) T cells. Immunity, 53(2), 335-352 e8.","journal-title":"Immunity"},{"issue":"16","key":"10378_CR83","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1182\/bloodadvances.2022007519","volume":"6","author":"P Milne","year":"2022","unstructured":"Milne, P., et al. (2022). Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E. Blood Advances, 6(16), 4901\u20134904.","journal-title":"Blood Advances"},{"issue":"5","key":"10378_CR84","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.hoc.2015.06.003","volume":"29","author":"M Collin","year":"2015","unstructured":"Collin, M., et al. (2015). Cell(s) of origin of Langerhans cell histiocytosis. Hematology\/Oncology Clinics of North America, 29(5), 825\u201338.","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"9","key":"10378_CR85","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJMra1607548","volume":"379","author":"CE Allen","year":"2018","unstructured":"Allen, C. E., Merad, M., & McClain, K. L. (2018). Langerhans-cell histiocytosis. New England Journal of Medicine, 379(9), 856\u2013868.","journal-title":"New England Journal of Medicine"},{"issue":"5600","key":"10378_CR86","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson, G. L., & Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298(5600), 1911\u20131912.","journal-title":"Science"},{"issue":"1\u20132","key":"10378_CR87","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbapap.2005.08.017","volume":"1754","author":"B Kaminska","year":"2005","unstructured":"Kaminska, B. (2005). MAPK signalling pathways as molecular targets for anti-inflammatory therapy\u2013from molecular mechanisms to therapeutic benefits. Biochimica et Biophysica Acta, 1754(1\u20132), 253\u2013262.","journal-title":"Biochimica et Biophysica Acta"},{"key":"10378_CR88","doi-asserted-by":"publisher","first-page":"1558263","DOI":"10.3389\/fimmu.2025.1558263","volume":"16","author":"KP Michalak","year":"2025","unstructured":"Michalak, K. P., & Michalak, A. Z. (2025). Understanding chronic inflammation: Couplings between cytokines, ROS, NO, Ca(i) (2+), HIF-1alpha, Nrf2 and autophagy. Frontiers in Immunology, 16, 1558263.","journal-title":"Frontiers in Immunology"},{"key":"10378_CR89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cyto.2017.05.026","volume":"97","author":"A Morimoto","year":"2017","unstructured":"Morimoto, A., et al. (2017). Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine, 97, 73\u201379.","journal-title":"Cytokine"},{"issue":"4","key":"10378_CR90","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/(SICI)1096-9896(199612)180:4<400::AID-PATH701>3.0.CO;2-W","volume":"180","author":"JH de Graaf","year":"1996","unstructured":"de Graaf, J. H., et al. (1996). The presence of cytokines in Langerhans\u2019 cell histiocytosis. The Journal of Pathology, 180(4), 400\u20136.","journal-title":"The Journal of Pathology"},{"issue":"5","key":"10378_CR91","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/JLB.3A0122-075RR","volume":"112","author":"D Minichino","year":"2022","unstructured":"Minichino, D., et al. (2022). BRAF-V600E utilizes posttranscriptional mechanisms to amplify LPS-induced TNFalpha production in dendritic cells in a mouse model of Langerhans cell histiocytosis. Journal of Leukocyte Biology, 112(5), 1089\u20131104.","journal-title":"Journal of Leukocyte Biology"},{"issue":"4","key":"10378_CR92","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019). The IL-17 family of cytokines in health and disease. Immunity, 50(4), 892\u2013906.","journal-title":"Immunity"},{"issue":"5","key":"10378_CR93","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.7150\/thno.103958","volume":"15","author":"X Wan","year":"2025","unstructured":"Wan, X., et al. (2025). Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37\/Hsp90 chaperone and the 14-3-3 scaffold. Theranostics, 15(5), 2035\u20132051.","journal-title":"Theranostics"},{"key":"10378_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/biom12070905","author":"DM Bjorklund","year":"2022","unstructured":"Bjorklund, D. M., et al. (2022). Recognition of BRAF by CDC37 and re-evaluation of the activation mechanism for the class 2 BRAF-L597R mutant. Biomolecules. https:\/\/doi.org\/10.3390\/biom12070905","journal-title":"Biomolecules"},{"issue":"7263","key":"10378_CR95","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature08314","volume":"461","author":"T Rajakulendran","year":"2009","unstructured":"Rajakulendran, T., et al. (2009). A dimerization-dependent mechanism drives RAF catalytic activation. Nature, 461(7263), 542\u2013545.","journal-title":"Nature"},{"issue":"15","key":"10378_CR96","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1073\/pnas.1102554108","volume":"108","author":"J Hu","year":"2011","unstructured":"Hu, J., et al. (2011). Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proceedings of the National Academy of Sciences of the United States of America, 108(15), 6067\u20136072.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7693","key":"10378_CR97","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature25478","volume":"554","author":"H Lavoie","year":"2018","unstructured":"Lavoie, H., et al. (2018). MEK drives BRAF activation through allosteric control of KSR proteins. Nature, 554(7693), 549\u2013553.","journal-title":"Nature"},{"key":"10378_CR98","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1016\/j.csbj.2021.06.007","volume":"19","author":"RC Maloney","year":"2021","unstructured":"Maloney, R. C., et al. (2021). The mechanism of activation of monomeric B-Raf V600E. Computational and Structural Biotechnology Journal, 19, 3349\u20133363.","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"7377","key":"10378_CR99","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos, P. I., et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480(7377), 387\u2013390.","journal-title":"Nature"},{"issue":"38","key":"10378_CR100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2508169122","volume":"122","author":"DA Ritt","year":"2025","unstructured":"Ritt, D. A., et al. (2025). An in vitro BRAF activation assay elucidates molecular mechanisms driving disassembly of the autoinhibited BRAF state. Proceedings of the National Academy of Sciences of the United States of America, 122(38), Article e2508169122.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10378_CR101","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao, Z., et al. (2015). BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell, 28(3), 370\u2013383.","journal-title":"Cancer Cell"},{"issue":"6","key":"10378_CR102","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan, P. T., et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 116(6), 855\u2013867.","journal-title":"Cell"},{"key":"10378_CR103","doi-asserted-by":"publisher","unstructured":"Yap, J., et al. (2021). The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of alphaC-beta4 loop. Science Advances, 7(24):eabg0390. https:\/\/doi.org\/10.1126\/sciadv.abg0390","DOI":"10.1126\/sciadv.abg0390"},{"issue":"4","key":"10378_CR104","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ccell.2016.02.010","volume":"29","author":"SA Foster","year":"2016","unstructured":"Foster, S. A., et al. (2016). Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. Cancer Cell, 29(4), 477\u2013493.","journal-title":"Cancer Cell"},{"issue":"3","key":"10378_CR105","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1158\/2159-8290.CD-15-0896","volume":"6","author":"SH Chen","year":"2016","unstructured":"Chen, S. H., et al. (2016). Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discovery, 6(3), 300\u2013315.","journal-title":"Cancer Discovery"},{"key":"10378_CR106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107207118","author":"GL Gonzalez-Del Pino","year":"2021","unstructured":"Gonzalez-Del Pino, G. L., et al. (2021). Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation. Proceedings of the National Academy of Sciences of the United States of America. https:\/\/doi.org\/10.1073\/pnas.2107207118","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"13","key":"10378_CR107","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","volume":"73","author":"N Ishii","year":"2013","unstructured":"Ishii, N., et al. (2013). Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Research, 73(13), 4050\u20134060.","journal-title":"Cancer Research"},{"issue":"4","key":"10378_CR108","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/bloodadvances.2022007947","volume":"7","author":"PG Kemps","year":"2023","unstructured":"Kemps, P. G., et al. (2023). Clinicogenomic associations in childhood Langerhans cell histiocytosis: An international cohort study. Blood Advances, 7(4), 664\u2013679.","journal-title":"Blood Advances"},{"issue":"1","key":"10378_CR109","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5114\/pdia.2017.67095","volume":"35","author":"M Jezierska","year":"2018","unstructured":"Jezierska, M., et al. (2018). Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Postepy Dermatologii i Alergologii, 35(1), 6\u201317.","journal-title":"Postepy Dermatologii i Alergologii"},{"issue":"16","key":"10378_CR110","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/blood.2019002766","volume":"135","author":"J Haroche","year":"2020","unstructured":"Haroche, J., Cohen-Aubart, F., & Amoura, Z. (2020). Erdheim-Chester disease. Blood, 135(16), 1311\u20131318.","journal-title":"Blood"},{"issue":"7","key":"10378_CR111","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","volume":"11","author":"C Adamopoulos","year":"2021","unstructured":"Adamopoulos, C., et al. (2021). Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling. Cancer Discovery, 11(7), 1716\u20131735.","journal-title":"Cancer Discovery"},{"issue":"4","key":"10378_CR112","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu, F., et al. (2018). Targeting ERK, an Achilles\u2019 heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica. B, 8(4), 552\u2013562.","journal-title":"Acta Pharmaceutica Sinica. B"},{"key":"10378_CR113","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/CMAR.S88825","volume":"10","author":"G Goel","year":"2018","unstructured":"Goel, G. (2018). Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a \u201cme too\u201d drug? Cancer Management and Research, 10, 425\u2013437.","journal-title":"Cancer Management and Research"},{"issue":"12","key":"10378_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110800","volume":"301","author":"E Tkacik","year":"2025","unstructured":"Tkacik, E., et al. (2025). Characterization and inhibitor sensitivity of ARAF, BRAF, and CRAF kinases. Journal of Biological Chemistry, 301(12), Article 110800.","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"10378_CR115","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/0008-5472.CAN-17-2033","volume":"78","author":"W Shao","year":"2018","unstructured":"Shao, W., et al. (2018). Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF. Cancer Research, 78(6), 1537\u20131548.","journal-title":"Cancer Research"},{"key":"10378_CR116","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jpba.2018.12.038","volume":"166","author":"X Yao","year":"2019","unstructured":"Yao, X., et al. (2019). A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 166, 20\u201329.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"23","key":"10378_CR117","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1158\/0008-5472.CAN-13-1825","volume":"73","author":"A Nakamura","year":"2013","unstructured":"Nakamura, A., et al. (2013). Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Research, 73(23), 7043\u20137055.","journal-title":"Cancer Research"},{"issue":"8","key":"10378_CR118","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/oncolo\/oyae119","volume":"29","author":"MV Nelson","year":"2024","unstructured":"Nelson, M. V., et al. (2024). Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) arm G. The Oncologist, 29(8), 723-e1093.","journal-title":"The Oncologist"},{"issue":"18","key":"10378_CR119","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/bloodadvances.2022009067","volume":"7","author":"D Evseev","year":"2023","unstructured":"Evseev, D., et al. (2023). Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH. Blood Advances, 7(18), 5246\u20135257.","journal-title":"Blood Advances"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10378-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10378-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10378-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:02:28Z","timestamp":1789070548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10378-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":119,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["10378"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10378-3","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm their consent to publish the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"66"}}